Drugs / KOSN-1724
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01379287 | Jun 2011 → Jan 2023 | cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KOSN-1724 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297393 ↗ |
| Known as | Iso-Fludelone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01379287 ↗ |
| Modality | Small molecule | — CHEMBL4297393 ↗ |
| Route | Intravenous | “Iso-fludelone will be administered IV over 6 hours (+/- 30 mins) on Day 1 of every 3 week cycle.” NCT01379287 ↗ |